New ARB technology rejuvenates existing antibiotics to outsmart antibiotic resistance

British biopharma firm Helperby Therapeutics, a spin-out drug discovery company from St George’s University of London, has developed a novel answer to the clear and present danger of antimicrobial resistance - Antibiotic Resistance Breakers (ARBs).

Doctors increasingly rely on last resort antibiotics such as carbapenems and colistin, but as harmful bacteria continue to mutate, this final line of resistance will eventually fail.

Helperby’s solution to this critical problem, and ground-breaking innovation, is Antibiotic Resistance Breakers - novel technology that rejuvenates existing antibiotics into long-term effective combination therapies.